Tanja Kuehbacher

1.8k total citations · 1 hit paper
34 papers, 733 citations indexed

About

Tanja Kuehbacher is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Tanja Kuehbacher has authored 34 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 14 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in Tanja Kuehbacher's work include Inflammatory Bowel Disease (29 papers), Microscopic Colitis (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Tanja Kuehbacher is often cited by papers focused on Inflammatory Bowel Disease (29 papers), Microscopic Colitis (13 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Tanja Kuehbacher collaborates with scholars based in Germany, Russia and Belgium. Tanja Kuehbacher's co-authors include Stefan Schreiber, Adrian Goldiș, Annegret Van der Aa, Chantal Tasset, Maria Kłopocka, Séverine Vermeire, Róbert Sike, Pille Harrison, Xavier Roblin and Robert Petryka and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

Tanja Kuehbacher

33 papers receiving 726 citations

Hit Papers

Clinical remission in patients with moderate-to-severe Cr... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
    2016 344 citations Séverine Vermeire, Stefan Schreiber et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tanja Kuehbacher Germany 10 422 261 172 150 130 34 733
Taku Kobayashi Japan 12 522 1.2× 332 1.3× 361 2.1× 110 0.7× 201 1.5× 41 903
Ulrike Billmeier Germany 11 368 0.9× 196 0.8× 445 2.6× 191 1.3× 122 0.9× 16 847
Paolo Pierani Italy 14 240 0.6× 305 1.2× 70 0.4× 247 1.6× 100 0.8× 27 962
P. Vavassori Italy 14 324 0.8× 217 0.8× 344 2.0× 192 1.3× 276 2.1× 18 951
Jodie Ouahed United States 9 426 1.0× 161 0.6× 434 2.5× 171 1.1× 219 1.7× 18 844
A D Levine United States 11 233 0.6× 180 0.7× 410 2.4× 167 1.1× 82 0.6× 19 856
Katsuyuki Kitoh Japan 11 190 0.5× 121 0.5× 513 3.0× 111 0.7× 89 0.7× 19 773
Chris Stevens United States 8 174 0.4× 138 0.5× 131 0.8× 114 0.8× 82 0.6× 10 538
Camilla Salvestrini United Kingdom 11 351 0.8× 237 0.9× 128 0.7× 161 1.1× 182 1.4× 20 744
R Tersigni Italy 12 486 1.2× 245 0.9× 574 3.3× 154 1.0× 313 2.4× 44 1.2k

Countries citing papers authored by Tanja Kuehbacher

Since Specialization
Citations

This map shows the geographic impact of Tanja Kuehbacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Kuehbacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Kuehbacher more than expected).

Fields of papers citing papers by Tanja Kuehbacher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanja Kuehbacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Kuehbacher. The network helps show where Tanja Kuehbacher may publish in the future.

Co-authorship network of co-authors of Tanja Kuehbacher

This figure shows the co-authorship network connecting the top 25 collaborators of Tanja Kuehbacher. A scholar is included among the top collaborators of Tanja Kuehbacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanja Kuehbacher. Tanja Kuehbacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lichtenstein, Gary R., Jessica R. Allegretti, Edward V. Loftus, et al.. (2024). P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme. Journal of Crohn s and Colitis. 18(Supplement_1). i1320–i1322.
2.
Dignaß, Axel, Wolfgang Stremmel, M. Horyński, et al.. (2023). Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Gastroenterology and Hepatology. 22(4). 810–820.e7. 2 indexed citations
3.
Ferrante, Marc, Peter M. Irving, Christian P. Selinger, et al.. (2022). Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opinion on Drug Safety. 22(2). 141–152. 20 indexed citations
4.
Panaccione, Remo, Bruce E. Sands, Silvio Danese, et al.. (2022). Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY. Gastroenterology. 162(7). S–963. 1 indexed citations
5.
Irving, Peter M., B E Sands, Timothy Hoops, et al.. (2021). OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study. Journal of Crohn s and Colitis. 15(Supplement_1). S001–S002. 18 indexed citations
6.
D’Haens, Geert, Stefan Schreiber, Tanja Kuehbacher, et al.. (2017). DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease. Journal of Crohn s and Colitis. 11(suppl_1). S70–S71. 1 indexed citations
7.
Kuehbacher, Tanja, et al.. (2017). Combination Therapy of Vedolizumab and a TNF Antagonist in IBD Patients with Severe Chronic Active, Therapy Refractory Disease Course. Gastroenterology. 152(5). S398–S398. 1 indexed citations
8.
Vermeire, Séverine, Stefan Schreiber, Robert Petryka, et al.. (2016). Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. The Lancet. 389(10066). 266–275. 344 indexed citations breakdown →
9.
Vermeire, Séverine, Stefan Schreiber, Tanja Kuehbacher, et al.. (2016). Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the Phase 2 FITZROY study. 5 indexed citations
10.
Ellrichmann, Mark, Susanna Nikolaus, Alexander Arlt, et al.. (2014). Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Alimentary Pharmacology & Therapeutics. 39(8). 823–833. 59 indexed citations
11.
Derer, Stefanie, Andreas Till, Robert Haesler, et al.. (2012). mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut. 62(3). 376–386. 22 indexed citations
12.
Franke, André, Tanja Kuehbacher, Susanna Nikolaus, Philip Rosenstiel, & Stefan Schreiber. (2011). The Complete Individual Genome of a Female Crohn's Disease Patient – What Can You Learn?. Gastroenterology. 140(5). S–90. 2 indexed citations
13.
Fritscher‐Ravens, Annette, Mark Ellrichmann, Susanna Nikolaus, et al.. (2011). 463 Endoscopic Ultrasound of the Colon for the Differentiation of Crohn's Disease and Ulcerative Colitis in Comparison to Healthy Controls - A Prospective, Blinded, Comparative Study. Gastrointestinal Endoscopy. 73(4). AB128–AB128. 3 indexed citations
14.
15.
Kuehbacher, Tanja, Susanna Nikolaus, & Stefan Schreiber. (2011). Serum Soluble IL2-Receptor is Increased in a Subpopulation of Crohns Disease Patients, Who Respond to Open Label Use of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40. Gastroenterology. 140(5). S–589. 4 indexed citations
16.
Ufer, Mike, K. Dilger, Igor Mosyagin, et al.. (2008). Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Expression on Budesonide Pharmacokinetics: A Possible Role of Intestinal CYP3A4 Expression. Clinical Pharmacology & Therapeutics. 84(1). 43–46. 21 indexed citations
17.
Kuehbacher, Tanja, Ateequr Rehman, Patricia Lepage, et al.. (2008). Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. Journal of Medical Microbiology. 57(12). 1569–1576. 144 indexed citations
18.
Rosenstiel, Philip, Massimo Fantini, Georg H. Waetzig, et al.. (2003). TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology. 124(4). A111–A111. 2 indexed citations
19.
Andus, Tilo, Hans Herfarth, Florian Obermeier, et al.. (2001). Improvement of arthritis/arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease. Gastroenterology. 120(5). A621–A621. 10 indexed citations
20.
Schreiber, Stefan, Tanja Kuehbacher, Silvia Mascheretti, et al.. (2000). Clinical efficacy of treatment with infliximab in a german multicenter, prospective, open-label trial in refractory crohn's disease. Gastroenterology. 118(4). A568–A568. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taku Kobayashi Breakdown of academic impact, for papers by Ulrike Billmeier Breakdown of academic impact, for papers by Paolo Pierani Breakdown of academic impact, for papers by P. Vavassori Breakdown of academic impact, for papers by Jodie Ouahed Breakdown of academic impact, for papers by A D Levine Breakdown of academic impact, for papers by Katsuyuki Kitoh Breakdown of academic impact, for papers by Chris Stevens Breakdown of academic impact, for papers by Camilla Salvestrini Breakdown of academic impact, for papers by R Tersigni
Rankless by CCL
2026